H.C. Wainwright Reaffirms Their Buy Rating on Aquestive Therapeutics (AQST)

By Carrie Williams

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Aquestive Therapeutics (AQSTResearch Report), with a price target of $15.00. The company’s shares closed last Thursday at $6.15.

According to TipRanks.com, Selvaraju is a top 100 analyst with an average return of 28.5% and a 57.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Black Diamond Therapeutics, and Biospecifics Technologies.

Currently, the analyst consensus on Aquestive Therapeutics is a Strong Buy with an average price target of $17.33, representing a 179.1% upside. In a report issued on May 15, Wedbush also maintained a Buy rating on the stock with a $31.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $10.00 and a one-year low of $1.41. Currently, Aquestive Therapeutics has an average volume of 836.6K.

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AQST in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.